(Q44203282)

30 November 2017

title

New water-soluble prodrugs of HIV protease inhibitors based on O-->N intramolecular acyl migration (English)

1 reference

30 November 2017

Yoshio Hamada

1

1 reference

30 November 2017

Jun Ohtake

2

1 reference

30 November 2017

Youhei Sohma

3

1 reference

30 November 2017

Tooru Kimura

4

1 reference

30 November 2017

Yoshio Hayashi

5

1 reference

30 November 2017

Yoshiaki Kiso

6

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Bioorganic & Medicinal Chemistry

30 November 2017

published in

1 reference

30 November 2017

volume

10

1 reference

30 November 2017

issue

12

1 reference

30 November 2017

page(s)

4155-4167

1 reference

Active human immunodeficiency virus protease is required for viral infectivity

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

The HIV-1 protease as a therapeutic target for AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

HIV protease: a novel chemotherapeutic target for AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Design and synthesis of substrate-based peptidomimetic human immunodeficiency virus protease inhibitors containing the hydroxymethylcarbonyl isostere

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Human immunodeficiency virus. Protease uninhibited

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Renin inhibitors containing hydrophilic groups. Tetrapeptides with enhanced aqueous solubility and nanomolar potency

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Water-soluble renin inhibitors: design of a subnanomolar inhibitor with a prolonged duration of action

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Peptidomimetic HIV protease inhibitors: phosphate prodrugs with improved biological activities

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

KNI-577, a potent small-sized HIV protease inhibitor based on the dipeptide containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Synthesis of 1-O-(2'-acetoxy)benzoyl-alpha-D-2-deoxyglucopyranose, a novel aspirin prodrug

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Prodrugs of vitamin E. 1. Preparation and enzymatic hydrolysis of aminoalkanecarboxylic acid esters of d-alpha-tocopherol

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Controlled drug release: new water-soluble prodrugs of an HIV protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Orally active water-soluble N,O-acyl transfer products of a beta,gamma-bishydroxyl amide containing renin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Synthesis and structure-activity relationships of bestatin analogues, inhibitors of aminopeptidase B

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Development of selective tight-binding inhibitors of leukotriene A4 hydrolase

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Eine neue Methode zur Synthese von Peptiden: Aktivierung der Carboxylgruppe mit Dicyclohexylcarbodiimid unter Zusatz von 1‐Hydroxy‐benzotriazolen

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Synthesis and biological evaluation of prodrug-type anti-HIV agents: ester conjugates of carboxylic acid-containing dipeptide HIV protease inhibitors and a reverse transcriptase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

'Double-Drugs'--a new class of prodrug form of an HIV protease inhibitor conjugated with a reverse transcriptase inhibitor by a spontaneously cleavable linker

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Increase in fluorescence upon the hydrolysis of tyrosine peptides: application to proteinase assays

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex

1 reference

https://api.crossref.org/works/10.1016%2FS0968-0896%2802%2900322-X

7 January 2021

10.1016/S0968-0896(02)00322-X

Identifiers

DOI

1 reference

30 November 2017

1 reference